• Monash IVF recorded FY25 Underlying EBITDA growth of 5.6% to $66.3m and Underlying NPAT of $27.4m
• Australian IVF industry stimulated cycles declined by 1.7% in FY25
• Independent Review into Brisbane and Clayton clinic incidents is complete, and Monash IVF has implemented many recommendations

Monash IVF Group Limited (MVF) reported FY25 results, with Underlying NPAT of $27.4m, down 8.1% but in line with revised guidance. Revenue grew 6.7% to $271.9m, and Underlying EBITDA increased 5.6% to $66.3m. The Australian IVF industry stimulated cycles declined by 1.7% in FY25, impacting MVF's domestic IVF business, which saw a 5.0% decrease in stimulated cycles. However, MVF's frozen embryo transfer cycles increased by 7.1%, and the company maintained a strong market share of 21.0% for stimulated cycles and 21.5% for frozen embryo transfers. MVF also addressed two unrelated incidents that occurred at its Brisbane and Clayton clinics, undertaking an Independent Review led by Fiona McLeod AO SC. The company has already implemented many of the review's recommendations and is committed to implementing the remainder. This includes enhanced nursing and laboratory protocols, additional verification processes, and increased staff training in custody and witnessing.Looking ahead, MVF's FY26 priorities include re-establishing its leading position in IVF and diagnostics through strong doctor and patient engagement, as well as enhancing its processes and systems. The company currently anticipates FY26 Underlying NPAT to be between $20-23m.

The Company currently anticipates FY26 Underlying NPAT to be between $20-23m.